Charles River Laboratories International, Inc. (NYSE:CRL) had its target price boosted by Jefferies Group LLC from $120.00 to $130.00 in a research note published on Monday. Jefferies Group LLC currently has a buy rating on the medical research company’s stock.

Other research analysts have also issued reports about the company. Zacks Investment Research lowered Charles River Laboratories International from a buy rating to a hold rating in a research report on Friday, August 11th. BidaskClub raised Charles River Laboratories International from a buy rating to a strong-buy rating in a research report on Tuesday, August 22nd. Barclays PLC reissued a hold rating and set a $102.00 price target on shares of Charles River Laboratories International in a research report on Wednesday, July 19th. Royal Bank Of Canada began coverage on Charles River Laboratories International in a research report on Tuesday, September 19th. They set a sector perform rating and a $110.00 price target on the stock. Finally, Citigroup Inc. reissued a neutral rating and set a $104.00 price target (up from $91.00) on shares of Charles River Laboratories International in a research report on Wednesday, June 28th. Six investment analysts have rated the stock with a hold rating, four have given a buy rating and one has assigned a strong buy rating to the stock. Charles River Laboratories International currently has an average rating of Buy and a consensus target price of $100.50.

Shares of Charles River Laboratories International (NYSE:CRL) opened at 112.59 on Monday. The company’s 50-day moving average price is $107.86 and its 200-day moving average price is $97.96. The stock has a market cap of $5.36 billion, a PE ratio of 29.67 and a beta of 0.96. Charles River Laboratories International has a 52-week low of $67.20 and a 52-week high of $113.83.

Charles River Laboratories International (NYSE:CRL) last announced its earnings results on Wednesday, August 9th. The medical research company reported $1.29 EPS for the quarter, beating the consensus estimate of $1.22 by $0.07. Charles River Laboratories International had a return on equity of 27.02% and a net margin of 10.13%. The business had revenue of $469.13 million during the quarter, compared to the consensus estimate of $458.25 million. During the same period in the prior year, the business posted $1.20 earnings per share. Charles River Laboratories International’s revenue was up 8.1% compared to the same quarter last year. Analysts expect that Charles River Laboratories International will post $5.10 earnings per share for the current year.

COPYRIGHT VIOLATION NOTICE: This report was originally published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this report on another website, it was illegally stolen and reposted in violation of U.S. & international trademark and copyright legislation. The legal version of this report can be read at https://www.thecerbatgem.com/2017/10/13/jefferies-group-llc-boosts-charles-river-laboratories-international-inc-crl-price-target-to-130-00.html.

In other Charles River Laboratories International news, Director George Massaro sold 3,830 shares of the company’s stock in a transaction dated Monday, July 17th. The stock was sold at an average price of $100.81, for a total value of $386,102.30. Following the transaction, the director now directly owns 18,731 shares of the company’s stock, valued at approximately $1,888,272.11. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, insider David Ross Smith sold 2,552 shares of the company’s stock in a transaction dated Monday, August 14th. The stock was sold at an average price of $67.10, for a total value of $171,239.20. Following the completion of the transaction, the insider now directly owns 11,671 shares in the company, valued at $783,124.10. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 22,529 shares of company stock worth $2,278,496. Insiders own 2.20% of the company’s stock.

Several institutional investors and hedge funds have recently added to or reduced their stakes in CRL. Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in shares of Charles River Laboratories International by 12.7% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,791 shares of the medical research company’s stock worth $181,000 after acquiring an additional 202 shares in the last quarter. Riverhead Capital Management LLC boosted its stake in shares of Charles River Laboratories International by 14.7% during the 2nd quarter. Riverhead Capital Management LLC now owns 1,931 shares of the medical research company’s stock worth $195,000 after acquiring an additional 247 shares in the last quarter. Cambridge Advisors Inc. bought a new stake in shares of Charles River Laboratories International during the 2nd quarter worth about $202,000. Advisor Partners LLC bought a new stake in shares of Charles River Laboratories International during the 2nd quarter worth about $208,000. Finally, Campbell & CO Investment Adviser LLC bought a new stake in shares of Charles River Laboratories International during the 2nd quarter worth about $217,000. Institutional investors own 95.38% of the company’s stock.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc is an early-stage contract research company. The Company is engaged in laboratory animal medicine and science (research model technologies) and develop a portfolio of discovery and safety assessment services, both good laboratory practice (GLP) and non-GLP, which supports its clients from target identification through non-clinical development.

Analyst Recommendations for Charles River Laboratories International (NYSE:CRL)

Receive News & Stock Ratings for Charles River Laboratories International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories International Inc. and related stocks with our FREE daily email newsletter.